Effects of agomelatine in rotenone-induced Parkinson's disease in rats

Gunaydin C., Avcı B., Bozkurt A., Önger M. E., Balci H., Bilge S. S.

NEUROSCIENCE LETTERS, vol.699, pp.71-76, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 699
  • Publication Date: 2019
  • Doi Number: 10.1016/j.neulet.2019.01.057
  • Journal Name: NEUROSCIENCE LETTERS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.71-76
  • Keywords: Agomelatine, Rotenone, Parkinson's disease, Rat, MELATONIN, MODEL, NEURODEGENERATION, PATHOGENESIS, ANTIOXIDANT, STRESS, PARP-1, SLEEP
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

The effects of melatonin and melatonin analogs in experimental Parkinson's disease (PD) models remain controversial. Agomelatine, a novel analog of melatonin, is both agonists for melatonin-1 and melatonin-2 receptors and antagonist of 5-HT2C receptors. While agomelatine has been commonly used as an anti-depressant and sleep drug, information about effects of agomelatine in PD are still lacking. Male Sprague-Dawley rats (220-260 g) were injected with rotenone (0.5 mu g, n = 16) or vehicle (1 mu l DMSO, n = 8) into the left substantia nigra (SN) and ventral tegmental area under stereotaxic surgery. After ten days, the rats were assessed for the confirmation of PD by the rotational test following apomorphine injection (2 mg/kg, i.p.).